Assessment of specific risks for the recurrence of deep vein thrombosis: a case report.

Cases Journal
Joshua A BoysHouria I Hassouna

Abstract

Venous thromboembolism is a multifactorial disease defined by multiple interactions between genetic and environmental components. It is managed by oral anticoagulation with warfarin sodium (Coumadin), a drug that targets the vitamin K epoxide reductase to prevent the recycling of vitamin K epoxide to the reduced form of vitamin K. The reduced form of vitamin K is an essential cofactor in the formation of active clotting factors II, VII, IX, X and regulatory factors protein C, and cofactor protein S through gamma-glutamyl carboxylation. The duration of Coumadin treatment, three to six months or life-long, should be based on the individual risk for recurrent deep vein thrombosis and on the associated increased risk for bleeding complications. A previously healthy 50-year-old white male developed a deep vein thrombosis consequent to surgical placement of a titanium rod to correct a fracture of the femur and he was maintained for over a year on daily oral doses of Coumadin 9 mg and aspirin 325 mg. When he began to bruise spontaneously with multiple large hematomas appearing without provocation, he requested that his primary care physician reconsider the anticoagulation. Because of his age, sex, and the possibility of an inherited o...Continue Reading

References

Jan 1, 1997·Pharmacology & Therapeutics·L S Kaminsky, Z Y Zhang
Mar 29, 2000·Archives of Internal Medicine·P O HanssonH Eriksson
Feb 18, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Thomas Hanslik, Jacques Prinseau
Jul 14, 2006·Journal of Thrombosis and Haemostasis : JTH·L YoungP Harper
Oct 2, 2007·Journal of Thrombosis and Thrombolysis·Giancarlo Agnelli, Cecilia Becattini

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

The American Journal of the Medical Sciences
Lily K CheungDavid J Hyman
Investigación clínica
M E MijaresC L Arocha-Piñango
International Journal of Rheumatic Diseases
Zahra RezaieyazdiElham Mokhtari-Amirmajdi
© 2022 Meta ULC. All rights reserved